BioLife Solutions Inc expected to post a loss of 34 cents a share - Earnings Preview

BioLife Solutions

27/02/2024 21:30

* BioLife Solutions Inc  BLFS.OQ   BLFS.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
29 for the period ending December 31 2023
    * The Bothell Washington-based  company is expected to
report a
24.5% decrease in revenue to $33.399 million from $44.26 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for BioLife Solutions Inc is
for a
loss of 34 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for BioLife
Solutions
Inc is $21.00​, above​ its last closing price of $17.60. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.38       -0.37      -0.30     Beat    20
 Jun. 30 2023  -0.21       -0.20      -0.23     Missed  -15
 Mar. 31 2023  -0.22       -0.21      -0.32     Missed  -51.3​
 Dec. 31 2022  -0.20       -0.17      -1.15     Missed  -590
 ​​Sep.        -0.18       -0.17      -0.23     Missed  -35.3
 30 2022                                                
 Jun. 30 2022  -0.23       -0.21      -0.06     Beat    72​
 Mar. 31 2022  -0.25       -0.25      -0.17     Beat    31.1
 Dec. 31 2021  -0.16       -0.17      -0.37     Missed  -119.5
 This summary was machine generated February 27 at 21:29 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)